FDA cracking down on Ozempic copycats, potentially slimming options for consumers

Weight-loss drug users may find themselves having to scale back.The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and Zepbound — the brand name of tirzepatide, threatening a workaround that allowed patients to access cheaper alternatives during shortages.Compounding pharmacies had been producing these off-brand versions under special allowances due to shortages of the FDA-approved medications.Since the FDA declared the shortages over, these flexibilities are being revoked, prompting drug compounders and telemedicine companies to scramble to find solutions to continue sales.The grace period for producing and selling compounded tirzepatide ended in March.

Thursday was the final cut-off for compounded semaglutide.These drugs mimic GLP-1 — the hormone the body naturally produces after eating — so users feel fuller for longer.The Outsourcing Facilities Association, a trade group representing compounding pharmacies, challenged the FDA’s decision in court, but judges upheld the agency’s authority to enforce the ban.This move is expected to tighten the supply of these medications, potentially leading to higher costs for patients who had relied on the more affordable compounded versions.“Patients who today can get the drug compounded for $350 a month will have no option but to pay $1,000 a month for Mounjaro or Zepbound, the Big Pharma name-brand versions that insurance usually won’t cover — if they can find it, that is,” former White House Press Secretary Sean Spicer wrote in The Post of the ban.

“Simply put, tirzepatide will become unaffordable overnight for many who rely on it.”Spicer, 53, noted that he’s “tried every weight-loss drug” and “GLP-1s have truly been a game changer” — which is why he believes this ban would greatly affect him and millions of other Americans who have come to depend on the budget-friendly drugs.“More than 12% of US adults have used GLP-...